Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637169 | 0.81 | RAB9A (0.44) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL6852546 | 0.81 | WNT3A (0.42) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL6215593 | 0.81 | MKNK1 (0.50) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL3118227 | 0.81 | HDAC4 (0.40) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL6854741 | 0.78 | EP300 (0.40) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL6852849 | 0.78 | HDAC4 (0.41) | PRMT5WDR77HDAC4DHODHWNT3A | |
| SCHEMBL8467926 | 0.78 | HDAC4 (0.46) | TAAR1PRMT5WDR77HDAC4DHODH | |
| SCHEMBL13625507 | 0.77 | XDH (0.42) | HDAC4DHODHWNT3AEP300 | |
| SCHEMBL13458062 | 0.75 | GABRA1 (0.52) | PRMT5WDR77HDAC4DHODHASIC3 | |
| SCHEMBL6880455 | 0.75 | EP300 (0.44) | LTA4HHDAC4DHODHWNT3AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103002897-B | Certain amino-pyridazines, compositions thereof, and methods of use thereof | 赛特凯恩蒂克公司 | 2017-06-09 | — | — | CN | claimed |
| WO-2025067540-A1 | PYRAZOLOTRIAZINE AND PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-03 | — | — | WO | disclosed |
| US-20100029669-A1 | 3-(SUBSTITUTED ETHYL)-RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029669-A1 | 3-(SUBSTITUTED ETHYL)-RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, RPS27, MRPL21 | CYP2A6 1021/4885ADRB2 2992/4885HRH3 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.